BCDA
BioCardia, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.94
+2.00%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.97
From 52W high−36.05%
Volume9272.00
Market cap$14.23M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$0.97
From 52W high
−36.05%
Volume
9272.00
Market cap
$14.23M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.4x
P/E (TTM)
—
RSI (14)
47.4
MomentumView details →
1D Return
+2.00%
YTD Return
−24.39%
SummaryUpdated Jun 1, 2026
BioCardia, Inc. (NASDAQ:BCDA) is a clinical-stage regenerative medicine company founded in 1996 and headquartered in Sunnyvale, California. The company develops cellular and cell-derived therapeutics primarily targeting cardiovascular and pulmonary diseases. BioCardia operates as a biotechnology company focused on advancing multiple therapeutic platforms through clinical trials, with particular emphasis on cell therapy treatments for heart failure and chronic myocardial ischemia. The company has been publicly traded since its IPO in November 1996 and currently maintains a small market capitalization as it progresses through various phases of clinical development.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration accepted BioCardia’s pre-submission package for marketing clearance of its Helix catheter.16d agoBioCardia announced that it will present a scientific poster on the CardiAMP HF II trial design at the Heart Failure Society of America Annual Scientific Meeting in Phoenix from October 9 to 12, 2026.28d agoBioCardia completed a revised Pre-Submission to the FDA's Center for Devices and Radiological Health under the Q-Submission program for approval of its Helix Catheter for therapeutic and diagnostic agent delivery to the heart.34d ago